Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study

Purpose: Steroid hormones in hormonal contraceptives influence a variety of metabolic parameters. Mainly, ethinyloestradiol (EE) combined (CHC) is potent inducer hepatic coagulation factors, has an impact on cholesterol and triglyceride levels glucose tolerance. Progestins CHC modify the oestrogen effects different ways, depending their pharmacologic properties. The progestin-only generally considered low.Methods: novel drospirenone (DRSP)-only pill (4 mg DRSP 24/4 intake) lipid-, carbohydrate- bone parameters haemostatic variables including clotting factors D-Dimer level was evaluated comparison to 0.075 desogestrel (DSG) during multicentric, prospective, double-blind, double-dummy clinical trial with 1190 participants over nine treatment cycles.Results: For both DSG, there decrease (total, HDL, LDL) levels. No relevant glucose, insulin, c-peptide or remodelling markers were detected groups. Considering coagulatory parameters, no hemostasis.Conclusions: results confirm beneficial properties drospirenone-only pill.EudraCT Number: 2011-002396-42